Login / Signup

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

Stefan KleinIsabella GashawSybille BaumannXinying ChangThomas HummelUwe ThußChristian Friedrich
Published in: British journal of clinical pharmacology (2022)
The PK profile, particularly the long half-life, and favourable tolerability with no taste-related adverse events, supports the further development of eliapixant in disorders with underlying P2X3 receptor-mediated neuronal hypersensitisation.
Keyphrases
  • open label
  • endothelial cells
  • double blind
  • induced pluripotent stem cells
  • placebo controlled
  • randomized controlled trial
  • clinical trial
  • pluripotent stem cells
  • brain injury
  • cerebral ischemia